tesamorelin + CJC-1295 + ipamorelin
updated
Tesamorelin + CJC-1295 + ipamorelin is a three-peptide blend: two growth-hormone-releasing hormone analogs plus ipamorelin, which acts on the ghrelin receptor. It is sold for sleep, body composition and recovery, pitched as three complementary growth-hormone pathways. Its evidence is the ingredients' own: no animal or human study has tested the blend, two of its parts hit the same receptor, and duration depends on whether the CJC is long-acting DAC or short no-DAC. Graded F for an untested combination of unverified identity; tesamorelin's HIV lipodystrophy approval does not transfer to it.
Two GHRH inputs + one ghrelin-receptor input
- Two GHRH inputs + one ghrelin-receptor input
- Three ingredients do not mean three independent pathways
Which CJC form is in the blend?
CJC-1295 with DAC is not interchangeable with material sold as CJC no DAC. The finished blend cannot inherit the long-acting construct’s exposure data until its exact identity is confirmed.
source: FDA · CJC forms and human exposure, FDA · CJC forms and human exposure
Has this exact combination been tested?
The cited PubMed and ClinicalTrials.gov records contain no controlled outcome study of this three-way blend. The human evidence concerns the individual ingredients, their receptor pharmacology, and different regimens.
source: Evidence for the exact combination, PubMed and ClinicalTrials.gov.
Does the third ingredient add a new mechanism?
Tesamorelin and CJC both act through the GHRH receptor family. Ipamorelin supplies the different ghrelin-receptor input. The mixture duplicates one arm of the proposed pathway; the cited clinical evidence contains no comparison establishing an advantage from doing so.
source: Egrifta WR · indication and risks, Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
What is the half-life of the triple blend?
No finished-product pharmacokinetic study measured a combined half-life. The ingredients persist differently, and CJC with DAC has a different exposure curve from material sold as CJC no DAC.
Can it use tesamorelin’s fat-loss evidence?
Egrifta WR’s labeled benefit is specific to excess abdominal fat in adults with HIV-associated lipodystrophy. Its data do not establish benefit from adding CJC and ipamorelin, or support general weight-loss claims for a triple blend.
What risks could overlap?
Tesamorelin can raise IGF-1 and is associated with glucose intolerance, fluid retention and hypersensitivity. The other ingredients introduce additional unresolved exposure and safety questions. The interaction between those effects has not been measured in the studies below.
What pre-existing conditions are particularly relevant?
The tesamorelin label contraindicates active malignancy, pregnancy, pituitary-axis disruption and hypersensitivity. It also requires attention to glucose and IGF-1. Adding two other GH-related agents does not establish a safe exception to those restrictions.
source: Egrifta WR · indication and risks
source: FDA · ingredient safety concerns, FDA · ingredient safety concerns
Is there a studied ratio, mixing method or cycle?
No study establishes a regimen for the finished blend. Egrifta preparation instructions apply to its own product, and the individual compounds’ study doses do not form a tested triple-blend protocol.
Studies and sources
Egrifta WR · indication and risks
FDA prescribing information
Egrifta WR (tesamorelin), US prescribing information, revised March 2025.
Egrifta WR is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management. The March 2025 label lists pituitary-axis disruption, active malignancy, pregnancy and hypersensitivity as contraindications. Warnings include elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. These are tesamorelin product findings, not a characterized safety profile for a blend.
Read the original sourceFDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for CJC-1295 and ipamorelin. Its CJC-1295 entry reports increased heart rate and a systemic vasodilatory reaction. Serious events, including deaths, occurred in an intravenous ipamorelin study, but the record does not establish causation or the risk of other routes.
Read the original sourceEvidence for the exact combination
Combination evidence
PubMed and ClinicalTrials.gov.
No controlled outcome study has tested this three-way blend. Human evidence covers the individual ingredients, their receptor pharmacology, and different regimens.
Why is tesamorelin + CJC-1295 + ipamorelin in F tier?
F reflects an unproven three-ingredient combination that duplicates the GHRH-receptor input. No clinical comparison has tested outcomes with and without the third ingredient.
how tiers are graded: methodology · every cited source · about reptides.
Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.